PHAS

PhaseBio Pharmaceuticals Inc.

Price

return (12m)

p/e

-0.02

p/bv

-0.02

DIVIDEND YIELD

0.00%

PHAS price

PhaseBio Pharmaceuticals

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*The amount considers the reinvestment of dividends.

Return on Investment PHAS

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

0.00%

1 year

0.00%

2 years

0.00%

5 years

0.00%

10 years

0.00%

Profitability Comparator

If you had invested

years ago

ago, you would now have:

Fundamentals PHAS

Valuation

P/E

-0.02

Sector -3.10

Industry -3.10

P/BV

-0.02

Sector 1.77

Industry 1.77

P/Revenue (PSR)

Sector 2.01

Industry 2.01

EV/EBITDA

Sector -216.68

Industry -216.68

EV/EBIT

Sector -46.14

Industry -46.14

P/EBITDA

0.07

Sector -21.54

Industry -21.54

P/EBIT

0.07

Sector -27.94

Industry -27.94

P/Total Assets

0.09

Sector 1.05

Industry 1.05

P/Net Current Assets

Sector -9.24

Industry -9.24

P/Working Capital

Sector -135.45

Industry -135.45

EPS

-2.09

Sector -1.78

Industry -1.78

BVPS

-2.39

Sector 1.99

Industry 1.99

Efficiency

Gross Margin

-3.35%

Sector 41.24%

Industry 41.24%

EBITDA Margin

-7,956.25%

Sector -17,192.92%

Industry -17,192.92%

EBIT Margin

-30.52%

Sector -35.37%

Industry -35.37%

Net Profit Margins

100.00%

Sector -35.81%

Industry -35.81%

Asset Turnover

0.01

Sector 0.03

Industry 0.03

Profitability

ROE

87.60%

Sector -57.47%

Industry -57.47%

ROA

-463.95%

Sector -59.48%

Industry -59.48%

ROIC

Sector -2,385.22%

Industry -2,385.22%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

Sector 2.92

Industry 2.92

Net Debt / EBITDA

Sector -21.38

Industry -21.38

Net Debt / EBIT

Sector -8.29

Industry -8.29

Net Debt / Equity

Sector -33,113.00

Industry -33,113.00

Gross Debt / Equity

Sector -0.84

Industry -0.84

Equity/Assets

-5.30

Sector 0.46

Industry 0.46

Liabilities/Assets

-5.30

Sector 0.41

Industry 0.41

Growth

5Y Revenue CAGR

0.00%

Sector -

Industry -

5Y Earnings CAGR

-4.74%

Sector -

Industry -

Fundamentals PHAS

DRAG THE FRAME TO SEE MORE DATA

Assets	Price ($)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
PHAS PhaseBio Pharmaceuticals Inc.	$0.00	-	0.00%	-0.02	-0.02	87.60%	100.00%
PFE Pfizer Inc.	$29.30	29.93%	5.91%	38.29	1.94	5.07%	6.80%
ABBV AbbVie Inc.	$283.02	27.22%	2.40%	79.71	-84.84	-106.44%	9.81%
NVO Novo Nordisk A/S	$38.44	-25.78%	4.74%	9.57	5.08	53.11%	35.32%
MRK Merck & Co. Inc.	$144.69	75.65%	2.34%	113.15	8.55	7.56%	4.77%
AZN AstraZeneca PLC	$165.06	-0.87%	1.95%	19.76	5.09	25.77%	16.95%
BMY Bristol-Myers Squibb Company	$58.66	42.28%	4.19%	13.18	5.48	41.59%	18.87%
ZTS Zoetis Inc.	$79.45	-43.79%	2.64%	12.52	10.49	83.77%	27.69%
AMGN Amgen Inc.	$426.52	46.68%	2.29%	26.86	20.10	74.80%	22.95%
REGN Regeneron Pharmaceuticals Inc.	$782.52	35.91%	0.47%	18.88	2.58	13.65%	27.86%
HALO Halozyme Therapeutics Inc.	$122.82	83.23%	0.00%	34.40	99.12	288.13%	24.86%
MCK McKesson Corporation	$994.67	27.04%	0.34%	25.91	-30.79	-118.84%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$502.58	20.58%	0.00%	29.00	6.31	21.76%	35.00%
CAH Cardinal Health Inc.	$250.05	61.38%	0.81%	34.89	-21.95	-62.92%	0.67%
ARGX argenx SE	$820.58	-2.74%	0.00%	13.83	3.67	26.52%	25.54%
HRMY Harmony Biosciences Holdings Inc.	$37.50	44.79%	0.00%	12.22	2.22	18.14%	18.88%
BIIB Biogen Inc.	$232.87	62.85%	0.00%	41.65	1.84	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

PHAS - Historical Dividends

no dividend paid in the period.

Current Dividend Yield

0.00%

5-year average Dividend Yield

0.00%

Current Payout

—

5-year average Payout

—

ABOUT PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Inc.

Average Investor10 user rating

4.0 (0 people)

United States

24 years

Founded: 2002

2018

Time since IPO - 8 years

50

Employees

PhaseBio Pharmaceuticals Inc. (United States) is listed on the Nasdaq and has a market capitalization of $1.97 million, with shareholders equity totaling $-117.40 million.

The company employs approximately 50 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, PhaseBio Pharmaceuticals Inc. reported $-10.00 million in revenue, generating net income of $-102.84 million.

Key financial metrics include a P/E ratio of -0.02, a price-to-book (P/B) ratio of -0.02, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker PHAS.

Market cap

$1.97 million

Net worth

$-117.40 million

$-117,398,000.00

Assets

$22.17 million

$22,166,000.00

Total Shares Outstanding

49.18 million

49,182,000

Average Daily Trading Volume

$2.21 million

$2,205,483.50

Sector

Health Care

Industry

Biotechnology

PHAS

PHAS revenue and profits

Financial Results PHAS

DRAG THE FRAME TO SEE MORE DATA

PHAS cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$994.67 27,04% (12M)

P/E

25.91

0.34%

ROE

-118.84%

P/BV

-30.79

CAH - Cardinal Health

$250.05 61,38% (12M)

P/E

34.89

0.81%

ROE

-62.92%

P/BV

-21.95

ABBV - AbbVie

$283.02 27,22% (12M)

P/E

79.71

2.40%

ROE

-106.44%

P/BV

-84.84

MRK - Merck & Co.

$144.69 75,65% (12M)

P/E

113.15

2.34%

ROE

7.56%

P/BV

8.55

AZN - AstraZeneca

$165.06 0,10% (12M)

P/E

19.76

1.95%

ROE

25.77%

P/BV

5.09

PFE - Pfizer

$29.30 29,93% (12M)

P/E

38.29

5.91%

ROE

5.07%

P/BV

1.94

BMY - Bristol-Myers Squibb

$58.66 42,28% (12M)

P/E

13.18

4.19%

ROE

41.59%

P/BV

5.48

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$994.67 27,04% (12 M)

P/L

25.91

0.34%

ROE

-118.84%

P/VP

-30.79

CAH - Cardinal Health

$250.05 61,38% (12 M)

P/L

34.89

0.81%

ROE

-62.92%

P/VP

-21.95

ABBV - AbbVie

$283.02 27,22% (12 M)

P/L

79.71

2.40%

ROE

-106.44%

P/VP

-84.84

MRK - Merck & Co.

$144.69 75,65% (12 M)

P/L

113.15

2.34%

ROE

7.56%

P/VP

8.55

AZN - AstraZeneca

$165.06 0,10% (12 M)

P/L

19.76

1.95%

ROE

25.77%

P/VP

5.09

PFE - Pfizer

$29.30 29,93% (12 M)

P/L

38.29

5.91%

ROE

5.07%

P/VP

1.94

BMY - Bristol-Myers Squibb

$58.66 42,28% (12 M)

P/L

13.18

4.19%

ROE

41.59%

P/VP

5.48

Frequently Asked Questions

What is the price of PhaseBio Pharmaceuticals (PHAS) today?

The current price of PhaseBio Pharmaceuticals (PHAS) is $0.00. The stock began the year trading around $0.00 and is currently priced at $0.00. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

When does PhaseBio Pharmaceuticals (PHAS) pay dividends?

PhaseBio Pharmaceuticals (PHAS) did not pay dividends over the past year.

Is PhaseBio Pharmaceuticals (PHAS) a good investment?

PhaseBio Pharmaceuticals (PHAS) is currently trading at $0.00 with a P/E ratio of -0.02. This represents a -2% premium compared to its historical average P/E. Over the past year, the stock paid $0.00 in dividends, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was 0.00%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy PhaseBio Pharmaceuticals (PHAS) stock?

You can buy PhaseBio Pharmaceuticals (PHAS) shares through any brokerage account that provides access to U.S. stock exchanges. After opening and funding your account, simply search for the ticker symbol PHAS and place a buy order. Before investing, consider factors such as your financial goals, risk tolerance, and overall portfolio allocation.

How much would 100 shares of PhaseBio Pharmaceuticals (PHAS) yield today?

Over the past month, PhaseBio Pharmaceuticals (PHAS) has returned 0.00% — 0.00% over the past year, and 0.00% over the past five years, including price appreciation and dividends.

In the last 12 months, the company paid a total of 0.00 per share in dividends, resulting in a dividend yield of 0.00%.

If you were to purchase 100 shares of PhaseBio Pharmaceuticals (PHAS) today at the current price of $0.00 your total investment would be $0.00.

Based on historical performance, the investment would have grown to approximately:

$0.00 after 1 year
$0.00 after 5 years
$0.00 after 10 years

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

PHAS

PhaseBio Pharmaceuticals Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment PHAS

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING PHAS WITH OTHER STOCK

ABOUT PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Inc.

United States

24 years

2018

50

PROFIT X PRICE PHAS

Financial Results PHAS

PHAS cash flow

Asset, Revenue and Profit Growth - PHAS

PHAS balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BMY - Bristol-Myers Squibb

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BMY - Bristol-Myers Squibb

Frequently Asked Questions